HT deprives prostate cancer cells of the androgen stimulation that promotes prostate cancer growth and progression, resulting in improvements in overall survival.4 HT is typically achieved through medical castration, or androgen deprivation, with luteinizing hormone-releasing hormone (LHRH) agonists with or without antiandrogen (AA) therapy. The gene discussed is GNRH1; the disease is Familial prostate cancer.